Known in the the US by its generic name Rimonabant, Acomplia is hailed as a miracle weight loss pill. It is considered an anoretic anti-obesity drug and the first CB1 receptor blocker to be approved for use. It has been made available to Europeans since 2006, but is still awaiting approval by the FDA. In Europe, Acomplia drug loss weight is indicated for use in conjunction with exercise and diet for patients who have a body mass index that is greater than 30 kg/m² (or greater than 27 kg/m² for those with risk factors, i.e. type 2 diabetes and dyslipidaemia).
According to studies, Acomplia drug loss weight helps people lose weight, but not that much. It is also claimed to lower cardiac risk factors, reduces abdominal fat, helps increase good cholesterol, lowe blood pressure, and even help people stop smoking. A study made by the State University of Rio de Janeiro, Brazil, found that the use of Acomplia after a year produces a modest weight loss of about five percent. A 20 milligram pill is said to reduce 4.9 kilograms more body weight in trials with one-year results, translating to a weight loss of under 11 pounds. Not exactly something to go crazy about.
Acomplia drug loss weight works by suppressing the appetite, by targeting the brain cells involved in the "munchies," the same brain cells that cause addiction to marijuana and food. They help maintain a weight loss plan but do not directly cause you to lose weight. The study claims that patients who stayed on the 20 milligram dosage seemed to maintain weight loss compared to those who were intaking placebo pills, who in contrast gained significant weight. Side effects of rimonabant were found to include dizziness, head ache, nausea, joint pain, and diarrhea.